Levocetirizine Dihydrochloride
Grundinformationen
- CAS
130018-87-0- Standard-SMILES
Cl.Cl.O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1- InChIKey
PGLIUCLTXOYQMV-GHVWMZMZSA-N- Summenformel
- C21H27Cl3N2O3
- Durchschnittliche Molmasse
- 461,8 g/mol
- Monoisotopische Masse
- 460,108726
Überblick
Levocetirizine Dihydrochloride is the dihydrochloride salt form of the active levorotatory enantiomer of cetirizine, levocetirizine; a third generation, non-sedating, selective histamine H1 receptor antagonist, with antihistamine, anti-inflammatory and potential anti-angiogenic activities. Levocetirizine competes with endogenous histamine for binding at peripheral H1-receptor sites on the effector cell surface. This prevents the negative symptoms associated with histamine release and an allergic reaction. In addition, as histamine plays an important role in angiogenesis during an allergic inflammatory reaction, blocking the action of histamine may modulate the expression of proangiogenic factors and thus may prevent angiogenesis. As a third-generation histamine H1 receptor antagonist, levocetirizine has fewer side effects than most second-generation antihistamines.
Namen und Bezeichner
- Bevorzugter Name
- Levocetirizine Dihydrochloride
- IUPAC
- 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid;dihydrochloride
- Englischer Name
- Levocetirizine dihydrochloride
- Summenformel
- C21H27Cl3N2O3
- Molmasse
- 461.81
Namen und Synonyme
Levocetirizine dihydrochloride130018-87-0XyzalSOD6A38AGAXyzal Allergy 24hrChildrens Xyzal Allergygood sense levocetirizinecetirizine (R)-form dihydrochlorideUCB-28556NSC-758898DTXSID30926567CETIRIZINE HYDROCHLORIDE (R)-
Weitere Namen anzeigen
LEVOCETIRIZINE 2HCLLEVOCETIRIZINE HCLLEVOCETRIZINE DIHYDROCHLORIDE(R)-Cetirizine diHCl (Levocetirizine diHCl)[2-[4-[(r)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetic acid dihydrochlorideDDDBLevocetrizineHClLevocetirizine HCILevocitirizine 2HCLLEVOCETIRIZINE DIHCL
Acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, dihydrochloride(2-(4-((R)-(4-Chlorophenyl)phenylmethyl)piperazin-1-yl)ethoxy)acetic acid dihydrochlorideXyzall(2-{4-[(R)-(4-Chlorophenyl)phenylmethyl]piperazin-1-yl}ethoxy)acetic acid dihydrochlorideAllery Relief 24HRAllergy Relief 24HRRefChem:55474DTXCID201355381
Eigenschaften
Berechnete Struktureigenschaften
- Polarare Oberfläche (TPSA)
- 53 Ų
- H-Brücken-Donoren
- 3
- H-Brücken-Akzeptoren
- 5
- Frei drehbare Bindungen
- 8
- Schwere Atome
- 29
- Formalladung
- 0
- Komplexität
- 443
Experimentelle und physikochemische Eigenschaften
Human Drugs
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Physikochemische Eigenschaften
- Schmelzpunkt
- 215 · 215-220°C
- storage temp.
- room temp
- Löslichkeit
- 2 O: · H2O: ≥23mg/mL
- Aggregatzustand
- powder
- Farbe
- White to Almost white
- Wasserlöslichkeit
- 2 O: · H2O: ≥23mg/mL
- Merck
- 14 · 14,2022
- Stabilität
- Hygroscopic
- InChI
- InChI=1/C21H25ClN2O3.2ClH/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26;;/h1-9,21H,10-16H2,(H,25,26);2*1H/t21-;;/s3
- InChIKey
- PGLIUCLTXOYQMV-MGIYCFTINA-N
- SMILES
- C(O)(=O)COCCN1CCN([C@@H](C2=CC=C(Cl)C=C2)C2=CC=CC=C2)CC1.[H]Cl.[H]Cl |&1:11,r|
- CAS Datenbank
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
GHS-Klassifizierung
GHS Classification
Warning
H302 (98.2%): Harmful if swallowed [Warning Acute toxicity, oral]
P264, P270, P273, P301+P317, P330, P391, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 111 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Gefahrenhinweise
Hazard Classes and CategoriesAcute Tox. 4 (98.2%)
Toxikologische Informationen
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Levocetirizine dihydrochloride
vLess-DILI-concern
4
Adverse reactions
DOI:10.1016/j.drudis.2016.02.015
Sicherheitsdaten
- wgk
- 3
- ridadr
- UN 3077 9 / PGIII
- hs_code
- 29335990
- RTECS-Nr.
- AG0990000
- risk_code
- 22-50/53
- hazard_code
- Xn,N
- safety_code
- 60-61
- Speicherklasse
- 11 - Combustible Solids
- Hazard Classifications
- Acute Tox. 4 OralAquatic Acute 1
Chemie und Industrie
Pharmakologische Informationen
FDA Pharmacological Classification
LEVOCETIRIZINE DIHYDROCHLORIDE
Histamine-1 Receptor Antagonist [EPC]; Histamine H1 Receptor Antagonists [MoA]
LEVOCETIRIZINE DIHYDROCHLORIDE 5 MG
Histamine H1 Receptor Antagonists [MoA]; Histamine-1 Receptor Antagonist [EPC]
ALLERY RELIEF 24HR
Histamine H1 Receptor Antagonists [MoA]; Histamine-1 Receptor Antagonist [EPC]
MeSH Pharmacological Classification
A class of non-sedating drugs that bind to but do not activate histamine receptors (DRUG INVERSE AGONISM), thereby blocking the actions of histamine or histamine agonists. These antihistamines represent a heterogenous group of compounds with differing chemical structures, adverse effects, distribution, and metabolism. Compared to the early (first generation) antihistamines, these non-sedating antihistamines have greater receptor specificity, lower penetration of BLOOD-BRAIN BARRIER, and are less likely to cause drowsiness or psychomotor impairment.
Anwendungen
VerwendenLevocetirizine dihydrochloride has been used as standard in the thin layer chromatography optimization and in preparation of racemic cetirizine standard for subcritical fluid chromatography-tandem mass spectrometry analysis.
Anbieter100 Anbieter
梯希爱(上海)化成工业发展有限公司021-67121386 · [email protected]
上海阿拉丁生化科技股份有限公司400-6206333 13167063860 · [email protected]
Hebei Yanxi Chemical Co., Ltd.+86-17531190177 · [email protected]
Jai Radhe Sales+(91)-(79)-26431096/65255722 · [email protected]
Zugehörige Reaktionen
1
Notizen zur Verbindung
Wird geladen…